CytRx Corporation operates as a biopharmaceutical research and development company specializing in oncology. Aldoxorubicin The company focuses on the clinical development of aldoxorubicin (formerly known as INNO-206), its modified version of the widely-used chemotherapeutic agent, doxorubicin. In 2014, the company initiated a pivotal Phase 3 trial of aldoxorubicin as a therapy for patients with soft tissue sarcoma (STS) whose tumors have progressed following treatment with chemotherapy, and the company has received approval from the U.S. Food and Drug Administration (FDA) to continue dosing patients with aldoxorubicin until disease progression in that clinical trial. The Phase 3 trial is being conducted under a Special Protocol Assessment (SPA), granted by the FDA. The company is in the process of evaluating aldoxorubicin in a global Phase 2b clinical trial in small cell lung cancer, a Phase 2 clinical trial in HIV-related Kaposi's sarcoma, a Phase 2 clinical trial in patients with late-stage glioblastoma (brain cancer), a Phase 1b trial in combination with ifosfamide in patients with soft tissue sarcoma, and a Phase 1b trial in combination with gemcitabine in subjects with metastatic solid tumors. The company has completed a global Phase 2b clinical trial with aldoxorubicin as a first-line therapy for STS, a Phase 1b/2 clinical trial primarily in the same indication, a Phase 1b clinical trial of aldoxorubicin in combination with doxorubicin in patients with advanced solid tumors and a Phase 1b pharmacokinetics clinical trial in patients with metastatic solid tumors. Research and Development The company’s expenditures for research and development activities related to continuing operations were $36.7 million, as of December 31, 2014. Intellectual Property Patents: As of March 9, 2015, the company held rights in 4 granted U.S. patents, 55 granted foreign patents, 1 pending U.S. application, 2 pending international applications (PCT), and 9 pending foreign patent applications covering aldoxorubicin and related technologies. The company’s intellectual property holdings relating to aldoxorubicin and related technologies include an exclusive license from KTB Tumorforschungs GmbH to U.S. and foreign patents and patent applications. Patents and applications that cover pharmaceutical compositions of aldoxorubicin, processes for their production, and their use in treatment methods have unextended patent terms expiring between June 2020 and June 2034. History CytRx Corporation, a Delaware corporation, was founded in 1985. The company was incorporated in 1985.
cytrx corp (CYTR:NASDAQ CM)
11726 San Vicente Boulevard
Los Angeles, CA 90049
|No competitor information is available for CYTR.|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
To contact CYTRX CORP, please visit www.cytrx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.